FDA Approves Lastacaft
FDA Approves Lastacaft (alcaftadine ophthalmic solution) for Prevention of Itching Associated with Allergic Conjunctivitis
July 28, 2010 -- The United States Food and Drug Administration (FDA) has approved Lastacaft (alcaftadine ophthalmic solution) for the prevention of itching associated with allergic conjunctivitis in patients over 2 years of age.
Alcaftadine is an H1 histamine receptor antagonist which also inhibits the release of histamine from mast cells.
The recommended dosage of Lastacaft is one drop to be instilled into each eye once daily.
Lastacaft should not be used to treat contact lens-related irritation.
In clinical trials, the most common side effects (occurring in < 4% of Lastacaft-treated eyes) were eye irritation, burning and/or stinging on instillation, eye redness, and eye itching.
The most common non-ocular side effects (occurring in < 3% of patients with Lastacaft-treated eyes) were nasopharyngitis, headache and influenza.
Lastacaft will be marketed by Vistakon Pharmaceuticals LLC and packaged in 5-mL bottles containing 3 mL alcaftadine ophthalmic solution 0.25% (2.5 mg/mL) preserved with benzalkonium chloride.
Posted: July 2010
Related articles
- Now Available Over the Counter, Lastacaft Provides Eye Allergy Itch Relief in Minutes that Lasts Through 16 Hours - March 16, 2022
Lastacaft (alcaftadine) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
